July 16th 2024
Laura W. Goff, MD, MSCI, MMHC, discusses the onslaught of treatment sequencing available in gastrointestinal cancer.
Community Practice Connections™: 8th Annual School of Gastrointestinal Oncology®
View More
2024 International Symposium of Gastrointestinal Oncology (ISGIO)
October 11-12, 2024
Register Now!
Community Practice Connections™: 5th Annual Precision Medicine Symposium – An Illustrated Tumor Board
View More
Community Oncology Connections™: Overcoming Barriers to Testing, Trial Access, and Equitable Care in Cancer
View More
The Next Wave in Biliary Tract Cancers: Leveraging Immunogenicity to Optimize Patient Outcomes in an Evolving Treatment Landscape
View More
Community Practice Connections™: 9th Annual School of Gastrointestinal Oncology®
View More
BURST CME™: Illuminating the Crossroads of Precision Medicine and Targeted Treatment Options in Metastatic CRC
View More
Fighting Disparities and Saving Lives: An Exploration of Challenges and Solutions in Cancer Care
View More
FDA Grants Fast Track Designation to CYNK-101 for HER2+ Gastric/GEJ Cancers
January 18th 2022CYNK-101 plus standard frontline chemotherapy, trastuzumab, and pembrolizumab has received a fast track designation from the FDA for patients with advanced HER2-positive gastric or gastroesophageal junction adenocarcinoma.
Abstracts From the 18th Annual Meeting of the International Society of Gastrointestinal Oncology
November 17th 2021The International Society of Gastrointestinal Oncology (ISGIO), hosted by Physicians’ Education Resource, LLC (PER®) presented the latest advances in the field of gastrointestinal cancer research.
Pembrolizumab Plus Chemotherapy Combination Improves Survival in Esophageal Squamous Cell Carcinoma
September 21st 2021Pembrolizumab plus chemotherapy compared with the placebo plus chemotherapy demonstrated an improvement in overall survival and progression-free survival for patients with esophageal squamous cell carcinoma.
NovoTTF-200T Delivery System Given a Breakthrough Designation by the FDA for Advanced Liver Cancer
September 10th 2021The NovoTTF-200T System was given a breakthrough designation by the FDA as treatment strategy that may work in conjunction with bevacizumab and atezolizumab to treat patients with advanced liver cancer.